NCT06662175View on ClinicalTrials.gov

Role of Dexmedetomidine as Synergistic Agent

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

September 30, 2025

Conditions
DexmedetomidineHyperbaric BupivacaineSubarachnoid Anesthesia
Interventions
DRUG

Hyperbaric bupivacaine

Group A (Unexposed) will received 2 ml of intrathecal bupivacaine

DRUG

hyperbaric bupivacaine and dexmedetomidine

Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion

Trial Locations (1)

25000

Lady Reading Hospital Mti Peshawar Kp Pakistan, Peshawar

All Listed Sponsors
lead

Lady Reading Hospital, Pakistan

OTHER_GOV

NCT06662175 - Role of Dexmedetomidine as Synergistic Agent | Biotech Hunter | Biotech Hunter